Phenytoin Dose Adjustment Based on Free Phenytoin Levels
Free phenytoin concentrations should be directly measured rather than calculated, and doses should be adjusted to maintain free levels between 1.0-2.0 mcg/mL (or 1-2 mg/L), with dose changes made cautiously due to phenytoin's nonlinear pharmacokinetics.
Target Therapeutic Range
The therapeutic range for free phenytoin is 1.0-2.0 mcg/mL 1. This corresponds to the traditional total phenytoin range of 10-20 mcg/mL when protein binding is normal, but critically ill patients, those with hypoalbuminemia, and children often have altered protein binding that makes total levels unreliable 2, 3, 4, 5.
Why Direct Measurement is Critical
Direct measurement of free phenytoin is superior to calculated estimates in several key populations:
Critically ill patients with hypoalbuminemia (albumin <2.5 g/dL): The Sheiner-Tozer equation underestimates free phenytoin in 33-35% of cases 3, 6. In one study, 10% of patients had toxic free levels despite therapeutic total levels 4.
Pediatric intensive care patients: Total phenytoin concentrations are particularly unreliable, with free fractions ranging from 0.06-0.42 (mean 0.13) compared to the expected 0.10 4. The Sheiner-Tozer equation failed to accurately predict free levels in this population.
Patients on valproic acid or cefazolin: These highly protein-bound drugs significantly increase free phenytoin fractions 4.
Uremic patients, pregnant women, and neonates: All demonstrate substantial variations in protein binding 5.
In one implementation study, 30% of patients showed discordance between therapeutic classification using free versus total phenytoin, rising to 53% in patients with abnormal free fractions 5.
Dose Adjustment Principles
Understanding Nonlinear Kinetics
Phenytoin exhibits saturable (Michaelis-Menten) kinetics 1, 7. This means:
- Small dose increases (even 10%) can produce disproportionately large increases in serum levels when concentrations are in the upper therapeutic range
- The half-life increases as levels rise
- Steady-state is reached in 7-10 days (5-7 half-lives) after any dose change 1
Practical Dosing Algorithm
When free phenytoin is subtherapeutic (<1.0 mcg/mL):
- If significantly below target: Increase daily dose by 50-100 mg (approximately 1-1.5 mg/kg)
- If mildly subtherapeutic: Increase by 30-50 mg daily
- Recheck free level in 7-10 days
When free phenytoin is supratherapeutic (>2.0 mcg/mL):
- If mildly elevated (2.0-2.5 mcg/mL): Decrease daily dose by 30-50 mg
- If significantly elevated (>2.5 mcg/mL): Hold 1-2 doses, then decrease daily dose by 50-100 mg
- Recheck free level in 7-10 days
When free phenytoin is therapeutic (1.0-2.0 mcg/mL):
- Continue current dose
- Monitor clinically for seizure control and toxicity symptoms (ataxia, nystagmus, tremor, somnolence) 8
Timing of Level Measurement
Optimal timing for therapeutic drug monitoring:
- Trough levels (just before next dose) are preferred for routine monitoring to assess steady-state and compliance 1
- Peak levels (4-12 hours post-dose for oral capsules) can identify dose-related toxicity threshold 1
- After loading doses: Measure at 2-4 hours to confirm adequate initial levels 9, 10
- After dose adjustments: Wait at least 7-10 days before rechecking to allow steady-state 1
Special Populations
Neonates and Infants (<6 months)
- Have increased risk of toxicity due to decreased protein binding 11
- Free phenytoin levels are particularly critical in this age group 4, 10
- Loading doses of 15-20 mg/kg often produce elevated free levels (mean 2.45-2.52 mg/L) 10
- Consider lower target ranges and more frequent monitoring
Patients with Hypoalbuminemia
- When albumin <2.5 g/dL, free fractions increase substantially (mean 0.22 vs normal 0.10) 4
- The relationship between free phenytoin and albumin is nonlinear 4
- Direct measurement is essential—do not rely on calculated corrections 3, 6
Critical Pitfalls to Avoid
Never use total phenytoin levels alone in critically ill patients, those with low albumin (<3.5 g/dL), renal failure, or on interacting medications 2, 3, 4, 5
Do not make dose changes more frequently than every 7-10 days unless clinically urgent, as steady-state has not been achieved 1
Avoid large dose increments when levels are already in the therapeutic range—even 10% increases can cause toxicity due to saturable kinetics 1
Do not assume the Sheiner-Tozer equation is accurate—it fails in 33-53% of high-risk patients 3, 6, 4
Monitor for drug interactions: Valproic acid, highly protein-bound antibiotics (cefazolin), and drugs metabolized by the same hepatic enzymes can significantly alter free phenytoin levels 12, 4